BAT8008 + BAT1308

BAT8008 + BAT1308 is a combination therapy under clinical investigation for advanced solid tumors. BAT8008 is an antibody-drug conjugate (ADC) targeting Trop2 (Trophoblast cell-surface antigen 2), designed to deliver a DNA topoisomerase I inhibitor payload directly to Trop2-expressing tumor cells, resulting in cytotoxicity and a bystander effect that may enhance efficacy against tumor heterogeneity. BAT1308 is a monoclonal antibody targeting PD-1 (Programmed cell death protein 1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. The combination is being evaluated for safety, tolerability, pharmacokinetics, and preliminary efficacy in multicenter phase 1/2 trials in patients with advanced solid tumors[1][2][3][4].